|
It’s THE MOST strategic level conference for biopharma
deal structure and strategy.
Windhover's Pharmaceutical Strategic Outlook is simply
where you will meet the most important people in the business.
In its heyday, Pharma was never among the most managerially
complex industries.
Strategy? “Add reps; increase R&D.” Finance? “With this cash flow, who cares?”
Dealmaking? “Buy what you need.”
No more. Facing its biggest challenges in decades – including cash-flow challenges
– Pharma and biotechs will depend for their survival on creative, effective strategic,
financial, marketing and dealmaking managers adapting and inventing new structures,
processes, cultures. Take the biggest debate in Pharma today – to diversify or to
focus on innovation. The diversifiers now have the task of managing very different
kinds of businesses – OTC and generics, very of which have shown much success with.
Meanwhile, the focusers are embarking on brand-new financial and deal strategies
designed to help them pay for their high-risk bets – with a dramatic increase in
the associated management complexity.
The 2009 PSO conference focuses squarely on these management challenges – particularly
in terms of how they affect finance and dealmaking.
We’ll bring you some of the industry’s most creative management and financial thinkers,
many of whom bring insights from other industries, with detailed case studies of
key deals and how they were managed; the new business-development processes; and
strategic advice from our picks for pharma’s best managers.
Windhover’s must-attend event examines and explains the most important
strategic alliances of the last year, and looks ahead to what the industry can
expect in the upcoming year.
At PSO you can:
- Meet your potential partner and find out how to approach them
- Benchmark your dealmaking against the best and the brightest
- Learn the deal values and deal specifics that let you calibrate deal-making
metrics
- Get key trend analysis on new business models, deal structures and deal
failures
- Maximize your strategic alliance opportunities by meeting business development
leaders who’ll share practical advice and strategies on how to structure
successful deals
- Walk away with practical, real-life lessons from some of the most experienced
dealmakers in the industry on how they evaluate opportunities and risk
BEYOND THE BASICS! PS0 attracts THE most strategic level speakers and
audience. Past speakers include:
Jim Cornelius
Chairman & CEO, Bristol-Myers Squibb
Peter Kellogg
CFO, Merck
Michael Wyzga
CFO, Genzyme
Ellen Strahlman, MD, VP
WW Business Development, Pfizer
Mark Wiggins
EVP, Corporate and Business Development, Biogen
Idec
Merv Turner, PhD
SVP, WW Licensing and External Research, Merck
& Co, Inc.
Thomas Hofstaetter, PhD
SVP, Corporate Business Development, Wyeth
|
*Located at the same venue and dates as BIO-Windhover
2009, The Partnering Meeting for Decision-Makers
Register for both PSO and BIO-Windhover and save 30% off each registration!
Maximize your strategic alliance opportunities by hearing CEOs, senior R&D
and senior business development executives share lessons learned, practical
advice and strategies on how to build your R&D pipeline – both internally
and externally. Take away the newest strategies and tactics that you can apply
to your company’s dealmaking efforts immediately!
And this April, PSO offers you an unbeatable line-up of Big Pharma and biotech
speakers to forecast trends and analyze changes in alliances and M&A. You’ll
hear from, and be able to quiz top industry executives and dealmakers.
PSO gathers top thinkers to grapple with the fundamental challenges facing
biotech and pharma – equipping dealmakers like you with the insights,
information and practical advice you'll need to strike successful deals. And
as always, you’ll be able to network and exchange ideas with an elite
group of your peers, your colleagues, your partners and your competitors.
This program will sell out so register early. Space is limited, so
register today!
What your colleagues and competitors
have to say about Pharmaceutical Strategic Outlook:
"It
was eye opening."
"The
conference was helpful in providing a big picture look at financing and
partnering trends in pharma/biotech."
"Windhover
conferences are on the top of my list. This was my first PSO meeting.
I'll definitely be back. The content provided a thorough and thoughtful
analysis of key industry trends with a eye towards the future. Plus, the
networking was great."
"I
always find the insight from Windhover to be novel, productive and very
thought-provoking. This conference was no exception."
"Excellent
meeting - great agenda, great speakers and intuitive questioning by the
moderators that extracted maxmium value from the sessions."
"Excellent,
it brought together all the thought leaders under one roof."
"Excellent.
The panel/session topics were relevant and thought provoking. The moderaters
did a great job of facilitating discussion/Q&A."
"I
thought many of the panels were very good, and there was an opportunity
to network with some new individuals."
"I
greatly enjoyed PSO. I thought it was distinctive from traditional conferences
in that pharma speakers did not sugarcoat their current dilemmas or spend
a lot of time promoting their companies. Instead, they admitted their
problems, presented their plans to deal with them and acknowledged the
current and likely effects those problems cause to their businesses. Such
honesty was refreshing ... and informative!"
"Great.
Panels were much more interesting than I was expecting (and my expectations
were pretty high)."
"A
great opportunity to hear not only the headlines of a deal, but exactly
how the two sides got there."
"Enjoyed
PSO very much, especially the fact that dealmakers actually talked about
the deals they had done in some depth and detail, unlike many other such
meetings where spin doctors have white washed the content so much that
nothing of meaning or import has been left behind."
"Excellent
conference with high quality speakers and topics."
"It
is interesting to know other company's business development strategies.
Especially it was a good arrangement to see them from both sides (Licensor
& Licensee, Big Pharma & Venture)."
"I
heard candid, rather than guarded, perspectives from Big Pharma really
provided honest insight into their objectives and suggests a changing
model in pharma's future regarding drug development, corporate operations
and biotech relationships. I also appreciated learning what is going on
with mergers, acquisitions and financing."
|
This meeting will sell out so register early and take advantage of
our early bird discounts! See you at the Marriott Marquis, New York City, this
April 13-15!
|